niacinamide has been researched along with Metabolic Diseases in 20 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
| " However, nicotinamide offers cellular protection in a specific concentration range, with dosing outside of this range leading to detrimental effects." | 2.72 | Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders. ( Maiese, K, 2021) |
| "Metabolic diseases impact all systems of the body and despite current therapies that offer some protection through tight serum glucose control, ultimately such treatments cannot block the progression of disability and death realized with metabolic disorders." | 2.66 | Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes. ( Maiese, K, 2020) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruf, S | 2 |
| Rajagopal, S | 2 |
| Kadnur, SV | 1 |
| Hallur, MS | 2 |
| Rani, S | 1 |
| Kristam, R | 2 |
| Swaminathan, S | 1 |
| Zope, BR | 1 |
| Gondrala, PK | 1 |
| Swamy, I | 2 |
| Putta, VPRK | 1 |
| Kandan, S | 1 |
| Zech, G | 2 |
| Schreuder, H | 2 |
| Rudolph, C | 1 |
| Elvert, R | 1 |
| Czech, J | 2 |
| Birudukota, S | 1 |
| Siddiqui, MA | 1 |
| Anand, NN | 1 |
| Mane, VS | 1 |
| Dittakavi, S | 1 |
| Suresh, J | 1 |
| Gosu, R | 1 |
| Ramesh, M | 1 |
| Yura, T | 1 |
| Dhakshinamoorthy, S | 2 |
| Kannt, A | 2 |
| Li, X | 1 |
| Yang, H | 1 |
| Jin, H | 1 |
| Turkez, H | 1 |
| Ozturk, G | 1 |
| Doganay, HL | 1 |
| Zhang, C | 1 |
| Nielsen, J | 1 |
| Uhlén, M | 1 |
| Borén, J | 1 |
| Mardinoglu, A | 1 |
| Maiese, K | 3 |
| Gao, Y | 1 |
| Martin, NI | 1 |
| van Haren, MJ | 1 |
| Li, D | 1 |
| Tian, YJ | 1 |
| Guo, J | 1 |
| Sun, WP | 1 |
| Lun, YZ | 1 |
| Guo, M | 1 |
| Luo, N | 1 |
| Cao, Y | 1 |
| Cao, JM | 1 |
| Gong, XJ | 1 |
| Zhou, SS | 1 |
| Wolak, N | 1 |
| Zawrotniak, M | 1 |
| Gogol, M | 1 |
| Kozik, A | 1 |
| Rapala-Kozik, M | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Iakovlev, AIu | 1 |
| Gordeeva, OS | 1 |
| Denisenko, AN | 1 |
| Vorontsov, AIu | 1 |
| Ulitin, DN | 1 |
| Shilov, VV | 1 |
| Andriaov, AY | 1 |
| Loladze, AT | 1 |
| Batotsyrenov, BV | 1 |
| HALVORSEN, K | 1 |
| HALVORSEN, S | 1 |
| DEMEULEMEESTER, F | 1 |
| DELAEY, P | 3 |
| HOOFT, C | 3 |
| TIMMERMANS, J | 3 |
| SNOECK, J | 3 |
| BROUET, G | 1 |
| MARCHE, J | 1 |
| Landauer, W | 1 |
| Vetter, K | 1 |
| Täufel, K | 1 |
8 reviews available for niacinamide and Metabolic Diseases
| Article | Year |
|---|---|
New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Humans; Metabolic Diseases; Models, Bi | 2020 |
Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.
Topics: Animals; Circadian Clocks; Humans; Metabolic Diseases; Niacinamide; Sirtuin 1; TOR Serine-Threonine | 2020 |
Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.
Topics: Animals; Humans; Metabolic Diseases; Neurodegenerative Diseases; Niacinamide; Oxidative Stress; Sign | 2021 |
Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target.
Topics: Enzyme Inhibitors; Humans; Metabolic Diseases; Neoplasms; Neurodegenerative Diseases; Niacinamide; N | 2021 |
Vitamins B1, B2, B3 and B9 - Occurrence, Biosynthesis Pathways and Functions in Human Nutrition.
Topics: Alzheimer Disease; Biological Availability; Dietary Supplements; Folic Acid; Humans; Metabolic Disea | 2017 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
[COMPLICATIONS OF A METABOLIC AND ENDOCRINE NATURE PRODUCED BY ANTIBACILLARY CHEMOTHERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Avitaminosis; Cycloserine; Endocrinology; Ethionamide; Is | 1964 |
Is insulin a teratogen?
Topics: Abnormalities, Drug-Induced; Animals; Beak; Brain; Chick Embryo; Congenital Abnormalities; Drug Inte | 1972 |
2 trials available for niacinamide and Metabolic Diseases
| Article | Year |
|---|---|
The acute effect of different NAD
Topics: Humans; Metabolic Diseases; NAD; Neurodegenerative Diseases; Niacin; Niacinamide; Nicotinamide Monon | 2023 |
[Postoperative correction of the methabolism of the single lung after pulmonectomy].
Topics: Adult; Aged; Drug Combinations; Enteral Nutrition; Flavin Mononucleotide; Follow-Up Studies; Humans; | 2011 |
10 other studies available for niacinamide and Metabolic Diseases
| Article | Year |
|---|---|
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.
Topics: Animals; Glucose; Humans; Metabolic Diseases; Mice; Niacinamide; Nicotinamide N-Methyltransferase; O | 2022 |
Novel Inhibitors of Nicotinamide-
Topics: Animals; Binding Sites; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Ligands; Metabo | 2021 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
[Approaches to the improvement of treatment efficacy in patients with acute severe asaleptin intoxication complicated by acute respiratory insufficiency of mixed genesis].
Topics: Acute Disease; Adult; Antipsychotic Agents; Clozapine; Drug Combinations; Female; Flavin Mononucleot | 2012 |
Hartnup disease.
Topics: Amino Acids; Hartnup Disease; Humans; Indoles; Metabolic Diseases; Niacin; Niacinamide; Pellagra; Pr | 1963 |
[THE CLINICAL FORM OF HARTNUP'S DISEASE].
Topics: Diagnosis, Differential; Friedreich Ataxia; Hartnup Disease; Humans; Indican; Indoles; Infant; Metab | 1963 |
BIOCHEMICAL ASPECTS OF THE HARTNUP DISEASE. I. RESULTS OF INTRAVENOUS AND ORAL TRYPTOPHAN LOADING TESTS IN A CASE OF HARTNUP DISEASE.
Topics: Amino Acid Metabolism, Inborn Errors; Biomedical Research; Friedreich Ataxia; Genetics, Medical; Har | 1964 |
BIOCHEMICAL ASPECTS OF THE HARTNUP DISEASE. II. SOME OBSERVATIONS ON RATS ABOUT TRYPTOPHAN METABOLISM.
Topics: Child; Clinical Enzyme Tests; Hartnup Disease; Humans; Indican; Indoles; Kidney; Kynurenine; Metabol | 1964 |
BIOCHEMICAL ASPECTS OF THE HARTNUP DISEASE. III. GENERAL DISCUSSION AND CONCLUSIONS.
Topics: Amino Acid Metabolism, Inborn Errors; Child; Drug Therapy; Feces; Hartnup Disease; Humans; Indican; | 1964 |
[Cereals in dietetics].
Topics: Calcium, Dietary; Carbohydrates; Diet; Diet Therapy; Edible Grain; Humans; Inositol; Intestinal Abso | 1971 |